Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
AssigneeUstav Experimentalni Botaniky Av Cr
InventorsJan Hanus, Vladimir Krystof, Marian Hajduch, Jaroslav Vesely, Miroslav Strnad
Life of this patent
Estimating the term…
Loading patent…
AssigneeUstav Experimentalni Botaniky Av Cr
InventorsJan Hanus, Vladimir Krystof, Marian Hajduch, Jaroslav Vesely, Miroslav Strnad
Estimating the term…
Various substituted nitrogen heterocyclic derivatives and their pharmaceutically acceptable salt derivatives are provided for use as medicaments, and particularly, as antimitotic, anti-viral, anti-cancer, anti-degenerative, immunosuppressive, and anti-microbial drugs or, vaccines. These heterocyclic derivatives can be used as an active agent in a pharmaceutical, as well as a diagnostic utility. To this end, several families of heterocyclic derivatives are provided including pyrrolopyrimidines, pyrazolopyrimidines, purines, and imidazopyridines. In particular, certain tri-substituted and tetra-substituted purines and pyrazolopyrimidines and their deaza analogues are provided for inhibiting cyclin-dependent kinase (“cdk”) proteins, viruses, and immunostimulation.
Substituted nitrogen heterocyclic derivatives of the formula I—
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Backward citations are indexed for grants only.
In which the condensed system contains two hetero rings: ortho-condensed systems
Drugs for disorders of the nervous system
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Antineoplastic agents
Term end not estimated
The present invention relates generally to new purine and pyrazolopyrimidine derivatives and their deaza analogues and to their use in suitable utilities, especially diagnostic and therapeutic methods.
The present invention relates, in particular, to purine derivatives and their inhibitory effect with respect to cyclin-dependent kinase proteins, abbreviated cdks and also with an inhibitory effect with respect to viruses and immunostimulation. Purine analogues as cdk inhibitors are disclosed for example in WO 97/16452, WO 98/05335 and WO97/20842. The teaching of these patents includes 2,6,9-trisubstituted and less substituted purine derivatives only.
Tetrasubstituted purines are disclosed in WO 98/01448 in which substituents are short hydrocarbonyl chains, usually represented by hydrogen. Substituents at C6 represents hydrogen or amine optionally substituted by one or two hydrocarbon groups; substituents at C8 are hydroxy, mercapto, acyloxy or oxycarbonyl substituted by aliphatic alkyl only. Nucleotide analogues containing phosphonate groups are disclosed for example in U.S. Pat. Nos. 4,659,825; 4,724,233; 5,124,051; 5,302,585; 5,208,221; 5,352,786; 5,356,886; 5,142,051; in EP publication numbers 269,947; 481,214; 630,381; 369,409; 454,427; 618,214; 398,231; 454,427; 468,119; 481,119; 481,214; 434,450 and in WO 95/07920; WO 94/03467; and WO96/33200. Typical purine base is adenine, 2,6-diaminopurine and guanine. The purine bases may include the deaza analogues thereof, 6,9-substituted and 2,6,9-trisubstituted purines and related analogues are disclosed in WO 96/33200. 2,8,9-, 6,8,9-trisubstituted and 2,6,8,9-tetrasubstituted purines and tri- and tetrasubstituted pyrazolopyrimidines and their deaza analogues have not yet been described.
1 mmol of 2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpurine was dissolved in chloroform and 1.1 mmol of bromine was added. The 8-bromo derivative hydrobromide was removed by filtration and crystallized from n-propanol—ether. M.p. 156-161° C. Yield 90%. TLC: chloroform-methanol (96:4), single spot. MS-ESI(+) m/z: 420, 422 [M+H]+ 1 TABLE 1 Compounds Prepared by the Method of Example 1 SUBSTITUENT C2 N6 C8 N9 2-hydroxyethylamino benzylamino bromo methyl 3-hydroxypropylamino benzylamino bromo isopropyl (R)-1-(hydroxymethyl) propylamino benzylamino bromo isopropyl (R)-1-(hydroxymethyl) propylamino 3-iodobenzylamino bromo isopropyl diethanolamino 3-chloroanilino bromo isopropyl (R)-1-(hydroxymethyl) isobutylamino 4-methoxybenzylamino bromo isopropyl (R)-1-(hydroxymethyl) isobutylamino 3-chloroanilino bromo isopropyl
2-(3-Hydroxypropylamino)-6-benzylamino-8-bromo-9-isopropylpurine (0.15 mmol), prepared as described in Example 1, was dissolved in 2 mL dimethylformamide, 0.9 mmol of CH3SNa was added and the mixture stirred at 40° C. for 1 hour. The solvent was removed in vacuo and the rest partitioned between water-EtOAc. The organic layer was dried, evaporated and the rest purified by column chromatography (silica gel, chloroform-heptane (8:2)). Yield 75%. M.p. 64-67° C. 1H NMR (300 MHz, CDCl3): 7.28-7.40 m, 5.55 t, 4.85 t, 4.75 d, 4.65 m, 3.62 m, 2.62 s, 1.74 dd, 1.60 d. MS-ESI(+) m/z: 387 [M+H]+ 2 TABLE 2 Compounds Prepared by the Method of Example 2 SUBSTITUENT C2 N6 C8 N9 2-hydroxyethylamino benzylamino methyl methyl 2-hydroxyethylamino benzylamino mercapto methyl 2-hydroxyethylamino benzylamino hydroxy methyl 2-hydroxyethylamino benzylamino amino methyl 2-hydroxyethylamino benzylamino 2-hydroxyethylamino methyl 2-hydroxyethylamino benzylamino aminomethylamino methyl 3-hydroxypropylamino benzylamino methyl isopropyl 3-hydroxypropylamino benzylamino mercapto isopropyl 3-hydroxypropylamino benzylamino hydroxy isopropyl 3-hydroxypropylamino benzylamino amino isopropyl 3-hydroxypropylamino benzylamino 2-hydroxyethylamino isopropyl 3-hydroxypropylamino benzylamino aminomethylamino isopropyl (R)-1-(hydroxymethyl) benzylamino methyl isopropyl propylamino (R)-1-(hydroxymethyl) benzylamino mercapto isopropyl propylamino (R)-1-(hydroxymethyl) benzylamino hydroxy isopropyl propylamino (R)-1-(hydroxymethyl) benzylamino amino isopropyl propylamino (R)-I-(hydroxymethyl) benzylamino 2-hydroxyethylamino isopropyl propylamino (R)-1-(hydroxymethyl) benzylamino aminomethylamino isopropyl propylamino (R)-1-(hydroxymethyl) 3-iodobenzylamino methyl isopropyl propylamino (R)-1-(hydroxymethyl) 3-iodobenzylamino mercapto isopropyl propylamino (R)-1-(hydroxymethyl) 3-iodobenzylamino hydroxy isopropyl propylamino (R)-1-(hydroxymethyl) 3-iodobenzylamino amino isopropyl propylamino (R)-1-(hydroxymethyl) 3-iodobenzylamino 2-hydroxyethylamino isopropyl propylamino (R)-1-(hydroxymethyl) 3-iodobenzylamino aminomethylamino isopropyl propylamino diethanolamino 3-chloroanilino methyl isopropyl diethanolamino 3-chloroanilino mercapto isopropyl diethanolamino 3-chloroanilino hydroxy isopropyl diethanolamino 3-chloroanilino amino isopropyl diethanolamino 3-chloroanilino 2-hydroxyethylamino isopropyl diethanolamino 3-chloroanilino aminomethylamino isopropyl (R)-1-(hydroxymethyl) 4-methoxybenzylamino mercapto isopropyl isobutylamino (R)-1-(hydroxymethyl) 4-methoxybenzylamino hydroxy isopropyl isobutylamino (R)-1-(hydroxymethyl) 4-methoxybenzylamino amino isopropyl isobutylamino (R)-1-(hydroxymethyl) 4-methoxybenzylamino 2-hydroxyethylamino isopropyl isobutylamino (R)-1-(hydroxymethyl) 4-methoxybenzylamino aminomethylamino isopropyl isobutylamino (R)-1-(hydroxymethyl) 3-chloroanilino methyl isopropyl isobutylamino (R)-1-(hydroxymethyl) 3-chloroanilino mercapto isopropyl isobutylamino (R)-1-(hydroxymethyl) 3-chloroanilino hydroxy isopropyl isobutylamino (R)-1-(hydroxymethyl) 3-chloroanilino amino isopropyl isobutylamino (R)-1-(hydroxymethyl) 3-chloroanilino 2-hydroxyethylamino isopropyl isobutylamino (R)-1-(hydroxymethyl) 3-chloroanilino aminomethylamino isopropyl isobutylamino
1 mmol of 6-(3-methoxybenzylamino)-2-chloro-9-isopropylpurine was brominated with 1.1 mmol of bromine as described in Example 1. The crude 2,8-dihalogeno derivative prepared was alkalinized with NH3/MeOH and extracted between water—EtOAc. The product crystallizes after partial evaporation of ethylacetate. M.p.123-125° C., yield 88%. MS-ESI (+) m/z 409.5, 411.4, 413.3 [M+H]+